Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.

ABSTRACT:

Purpose

We performed a case-control genome-wide association study (GWAS) to identify single nucleotide polymorphisms (SNPs) associated with musculoskeletal adverse events (MS-AEs) in women treated with aromatase inhibitors (AIs) for early breast cancer.

Patients and methods

A nested case-control design was used to select patients enrolled onto the MA.27 phase III trial comparing anastrozole with exemestane. Cases were matched to two controls and were defined as patients with grade 3 or 4 MS-AEs (according to the National Cancer Institute's Common Terminology Criteria for Adverse Events v3.0) or those who discontinued treatment for any grade of MS-AE within the first 2 years. Genotyping was performed with the Illumina Human610-Quad BeadChip.

Results

The GWAS included 2

SUBMITTER: Ingle JN 

PROVIDER: S-EPMC3020700 | biostudies-literature | 2010 Nov

REPOSITORIES: biostudies-literature